EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management

François Chasset, Alexandre Teboul iD

Journal of the European Academy of Dermatology and Venereology · 2026-05 · 40 (5) · 782-800

DOI: 10.1111/jdv.70186 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 02.12.2025. Verfasst von François Chasset und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, and INSERM U1135, CIMI, Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 215 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous lupus erythematosus (CLE) encompasses a spectrum of skin manifestations that may occur as an isolated dermatological condition or in association with systemic lupus erythematosus (SLE). This review provides an updated synthesis of current knowledge on CLE, including its classification, pathogenesis, clinical presentation and diagnostic strategy. It will discuss recent advances in pathogenesis, particularly the central role of type I interferons and interferon‐producing cells. Diagnostic evaluation involves clinical assessment, histopathology and immunological testing, with specific focus on CLE mimickers. In recent years, validated tools such as the Cutaneous Lupus Area and Severity Index (CLASI) have facilitated standardized assessment in clinical trials. Management of CLE requires a multifaceted approach incorporating general measures, topical therapies, antimalarials, systemic immunosuppressants and emerging biologics. Treatment should be tailored based on CLE subtype, severity, scarring risk and the presence or absence of systemic involvement. Antimalarials, particularly hydroxychloroquine, remain the cornerstone of systemic therapy. Second‐line or third‐line agents such as methotrexate, retinoids, dapsone, thalidomide and lenalidomide are recommended in refractory cases. Biological therapies, including belimumab and anifrolumab, are approved in the setting of SLE. Promising results from recent trials of targeted therapies including inhibitors of plasmacytoid dendritic cells, TLR7/8 and TYK2 are paving the way for novel treatment strategies in CLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousHumansAntimalarialsImmunosuppressive AgentsHydroxychloroquine

Stichwörter der Autor:innen

anifrolumabcutaneous lupus erythematosusdeucravacitinibenpatoransystemic lupus erythematosus

Substanzen

AntimalarialsImmunosuppressive AgentsHydroxychloroquine

Autor:innen und Institutionen

  • Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, and INSERM U1135, CIMI, Sorbonne University, Paris, France.
  • Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, Sorbonne University, Paris, France.

ORCID-Profile: Alexandre Teboul

Zitieren

APA

Chasset, F., & Teboul, A. (2026). Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management. Journal of the European Academy of Dermatology and Venereology, 40(5), 782-800. https://doi.org/10.1111/jdv.70186

Vancouver

Chasset F, Teboul A. Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management. Journal of the European Academy of Dermatology and Venereology. 2026;40(5):782-800. doi:10.1111/jdv.70186

BibTeX
@article{Chasset2026,
  author = {Chasset, François and Teboul, Alexandre},
  title = {Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {5},
  pages = {782--800},
  doi = {10.1111/jdv.70186}
}
Kostenlos starten →